A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
2020
Neurología (English Edition)
Preserved Fulltext
Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis. A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain. A group of multiple sclerosis specialists reviewed articles addressing treatment with alemtuzumab in patients with multiple sclerosis and published before December 2017. The included studies assessed the drug's efficacy,
doi:10.1016/j.nrleng.2019.11.001
pmid:36195374
fatcat:s6vf3wkswzbfnf2qrq5ci6lbru